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Various pathogenic bacteria have coats of polysaccharide, many with repeating epitopes.
Though polysaccharide vaccines have been available for some time, they induce mainly
IgM production, and are only moderately protective in adults and ineffective in young
children. It was originally shown in 1931 that the immunogenicity of polysaccharides
could be enhanced by conjugating to a protein. The last two decades have witnessed the
production and clinical testing of polysaccharide–protein conjugates specific for at least
four different bacteria which normally cause considerable mortality and morbidity,
especially in young children. In some cases, immunizing children from 4 months of
age, with a booster early in the second year, has resulted in remarkably high success rates
in protecting them from disease. For one pathogen, Haemophilus influenza type b, the
success rate has been sufficiently high (> 95%) to suggest that this disease might, in time,
be globally controlled in this way. The results of immunization with conjugate vaccines to
Streptococcus pneumoniae, Neisseria meningiditis and Salmonella typhi are also very encoura-
ging. More conjugate preparations are under development.
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I N T R O D U C T I O N
Some infectious agents express polysaccharide
molecules at their surface, e.g. encapsulated bac-
teria, or their surface proteins frequently have
complex carbohydrate side-chains, e.g. viruses
such as human immunodeficiency virus (HIV)
and influenza. These structures serve several pur-
poses. First, polysaccharides are less immunogenic
than many proteins, and second, particularly in
the case of glycoproteins, the sugar side-chain may
protect susceptible peptide bonds from attack by
proteases. In addition, these saccharides are some-
times involved in attachment of the agent to a
susceptible cell. All these features favor the survi-
val of the agent. For extracellular organisms in
particular, the composition of a surface polysac-
charide is determined solely by the organism’s
DNA and is therefore specific for the bacterium.
Landsteiner in 1924 [1] showed that, whereas a
small hapten molecule was non-immunogenic,
immunizing with the hapten linked to a protein
antigen induced an antihapten antibody response.
Polysaccharides were recognized as being rela-
tively poorly immunogenic, but Avery and Goebel
showed in 1929 that by conjugating a bacterial poly-
saccharide to a carrier protein, a stronger antibody
response to the carbohydrate moiety was obtained
[2]. The mechanism involved was completely un-
known at that time. The discovery of T helper cells
in the 1960s and their role in ‘helping’ B-cells make
antibody was a great leap forward in our under-
standing; antigens could now be described as T-cell
independent (TI) or T-cell dependent (TD).
I M M U N E R E S P O N S E S T O
T - C E L L - I N D E P E N D E N T A N D
T - C E L L - D E P E N D E N T A N T I G E N S
With TD antigens, an immune response can occur
at or shortly after birth, affinity maturation of the
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B-cell response takes place, immunologic memory
occurs, adjuvants can induce an enhanced
response, and there is a heterogeneous immuno-
globulin response [3].
Polymers bind directly to the IgM receptor on B-
cells, initiating an IgM antibody response. For
example, in adult rats, the polymeric flagella of
Salmonella induce an initial IgM response followed
by a long-lasting, strong IgG response. The mono-
meric protein flagellin induces only an IgG
response. In both cases, the IgG response is
induced by interaction of the B-cell with specific
activated Th2 cells.
TI antigens have been classified into two groups
[4]. The first group includes B-cell mitogens such
as lipopolysaccharides. The second group contains
the different polysaccharides which have repeat-
ing epitopes. The immune responses induced by
them have the following characteristics [4,5]:
1. Ontogeny—the response occurs 3–18 months
after birth in humans, but it varies with differ-
ent preparations; generally, children less than
2 years of age respond poorly.
2. There is no affinity maturation of the antibody
response; no immunologic memory and no
enhancement of the immune response by adju-
vants occurs.
3. Mainly (>90%) IgM is produced [6] and synthe-
sized in the spleen [7].
Polysaccharides also induce low levels of other
immunoglobulin responses, such as IgG and IgA,
so that they appear to have some of the character-
istics of a TD antigen. In one study [8], 36 of 40
adults developed specific IgG responses (IgG1,
IgG2 or both) to the 23-valent pneumococcal poly-
saccharide vaccine.
The switch to producing IgG by an IgM-secret-
ing B-cell usually requires interaction with an
activated, antigen-specific T helper (Th) lympho-
cyte. There is no indication that CD4þ Th cells with
an a,b-receptor recognize any products other than
classical MHC–peptide complexes. The activation
of human T-lymphocytes by lipopolysaccharide-
treated macrophages was found to be non-MHC
restricted but involved the co-stimulator B7 [9].
However g,d-T-cells may express non-classical
MHC antigens and recognize non-protein antigens
[10,11]. Nevertheless, there is no evidence that
these cells have receptors which recognize and
respond to processed polysaccharides.
Another critical step in achieving T-cell-depen-
dent B-cell activation is the interaction between
CD40 on B cells and its ligand. Using this pathway,
a fungal polysaccharide can induce the prolifera-
tion of CD4 T-cells, with the secretion of interleu-
kin-4 (IL-4) and IL-10 [12]. In another in vitro
system, addition of the CD40 ligand and a cyto-
kine, such as IL-4, has been shown to induce
immunoglobulin class switching by IgM B-cells
[13]. It therefore seems likely that such ‘non-anti-
gen-specific’ events, including some IgM-secreting
B-cells switching to produce antipolysaccharide
IgG or IgA, could occur in vivo.
T H E A D V A N T A G E S /
D I S A D V A N T A G E S O F
P O L Y S A C C H A R I D E V A C C I N E S
The major advantage of these vaccines is the rela-
tive simplicity of production of the different pre-
parations. The main disadvantage is the lack of a
protective immune response in young children,
where the need is very great. The pneumococcal
polysaccharide vaccine is recommended for the
elderly, but here also, the efficacy is variable.
C O N J U G A T E V A C C I N E S
The nature of the protein component and
conjugation
Several highly immunogenic proteins have been
proposed as the protein component, but, mainly,
four have been used [5]: diphtheria (D) or tetanus
(T) toxoids, CRM197 (a non-toxic variant of
diphtheria toxin), and a complex outer-membrane
protein (OMP) mixture from Neisseria meningitidis.
The polysaccharides or an oligosaccharide are
linked to the carrier, either directly or with carbon
spacers. The toxoids were chosen as the carrier
proteins because, apart from their inherent immu-
nogenicity, if the recipient had been earlier immu-
nized with the toxoid, a booster effect was
expected. However, under certain circumstances
(discussed later), suppressive effects can also
occur.
Immunogenicity and efficacy of conjugate
vaccines
A summary of the major findings on immunogeni-
city and efficacy for the different conjugate pre-
parations is presented in Table 1. Many of these
points are now considered in greater detail.
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The differences between conjugate and polysac-
charide vaccines are most marked for infants and
for the immunocompromised. Infants mount a
poor response to polysaccharides: this explains
the incidence of meningitis due to organisms with
a polysaccharide outer capsule being highest in the
first 2 years of life. Immunocompromised patients,
including those with HIV infection, may also
respond poorly to polysaccharides, and again con-
jugate vaccines have given a stronger immune
response [14].
Haemophilus influenzae type b (Hib)
Protection against Hib has long been known to
correlate with antibodies to the outer polysacchar-
ide type b capsule [15], made of polyribosyl ribitol
phosphate (PRP). The natural immune response to
PRP is poor under 18–24 months of age, and this is
the age of highest incidence of disease in non-
immunized populations. Early studies in Finland,
in which purified PRP was used as a vaccine,
showed a strong antibody response in children
aged 2–6 years, an intermediate response from
18 to 24 months of age, and no response at all
under 18 months of age [16]. The introduction of
the PRP vaccine resulted in a reduction in infec-
tions in children over 2 years of age, but no reduc-
tion in younger children [17].
When the Hib conjugate vaccines became avail-
able, one typical immunization schedule for
infants involved injections at 2, 4 and 6 months,
with a booster dose at between 9 and 15 months.
Four different H. influenzae conjugate preparations
were compared in four trials. PRP was conjugated
as follows: PRP–OMP, PRP–CRM197 and PRP–T.
An oligosaccharide–D (HbOC) preparation was
also made. PRP–OMP was found to be the most
potent; a response occurred after the first admin-
istration, and antibody titers >10 mg/L were
achieved. HbOC was the least potent [4]. Antibody
titers waned after the third dose, but responses to
all the preparations were significantly boosted
after the final dose. All preparations except HbOC
were licensed for use in the USA.
There is evidence that the conjugate vaccine
induces a substantial B-cell memory response, as
judged by a large increase in the level of specific
IgG formed, together with a significant increase in
antibody avidity after a boosting immunization.
Infants were immunized with PRP–T, diphtheria–
Table 1 Immunogenicity and efficacy of conjugate vaccines
Organism Protein carriers Immunogenicity Efficacy
Haemophilus
influenzae type b
Diphtheria toxoid
(modified)
Tetanus toxoid
N. meningitidis
OMP
Highly immunogenic
in infants and
immunocompromised
(far more so than
polysaccharide vaccine) [3–14]
95–100% effective
in eliminating all
Hib disease when used
in routine infant
schedule [16–20,22–24]
Streptococcus
pneumoniae
As for Hib Highly immunogenic
in infants and
immunocompromised
(far more so than polysaccharide
vaccine) [25–27]
94–97% protective
against all invasive
disease due to serotypes in
vaccine [28] 57% effective
against otitis media caused by
vaccine serotypes, but only 6%
against all otitis media due to
serotype replacement [29]
Serotype 19F immunogenic, but
poorly protective [29]
Neisseria
meningitidis
Diphtheria toxoid
(modified)
Tetanus toxoid
Highly immunogenic from
infancy [31,32] (conjugate far
more immunogenic than
polysaccharide [30–32])
92% protective in toddlers and
97% in teenagers [33]
Salmonella
typhi
Pseudomonas
aeruginosa exotoxin A
Immunogenic in humans
over 2 years old [34,35]
91.5% protective in 2–5-year-old
children [35]
Group B
streptococcus
Tetanus toxoid
Cholera toxin B (nasal)
Immunogenic in animals [36–39]
and adult humans [40]
Protective in animals [36–39]
No human data on protection
Staphylococcus
aureus
Pseudomonas
aeruginosa
exotoxin A
Immunogenic in
animals [41,42]
and humans
A single dose had 57% efficacy
over 40 weeks in patients
receiving hemodialysis [42]
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tetanus–acellular pertussis (DTP) and oral polio
vaccine at 2, 3 and 4 months of age [18]. A booster
dose of the conjugate was given at 1 year of age.
Serum samples were obtained at 5, 11 and
13 months of age. Mean specific IgG levels at these
three times were 6.23, 0.40 and 139.86 mg/mL. The
mean avidity index of 0.28 at 5 months had
increased to 0.52 at 13 months. It is, of course,
too early to know whether the protection achieved
by this immunization schedule persists for many
years, but the results are encouraging.
The introduction of conjugate vaccines led to a
rapid and sustained reduction in all Hib infections
[17,19]. This reduction was more precipitate than
would have been expected from the vaccine cover-
age, and further studies [20,21] showed that the
Hib conjugate vaccines induced a local immune
response, which resulted in reduced nasal carriage
of Hib, and thus to reduced exposure of suscep-
tible organisms. Thus, there was a herd immune
effect of Hib immunization. In populations where
one of the Hib conjugate vaccines has been intro-
duced as a universal infant vaccine, including the
USA, the UK, Finland, Iceland and Australasia, the
reduction in all Hib infections has been between
95% and 100% [3,17,19,22–24]. Effective vaccines
have used tetanus toxoid, CRM197 or OMPs of N.
meningiditis as carrier proteins. When tetanus tox-
oid is used as the carrier protein and the infant has
been primed with a prior dose of tetanus toxoid,
the antibody response to PRP is enhanced (‘carrier
priming’). In the UK, infants aged 3–11 months
were highly protected within 1 week of their first
dose of PRP–T vaccine [22]. H. influenzae disease
has the great advantage of being caused predomi-
nantly by a single serotype, Hib.
Streptococcus pneumoniae
In contrast to Hib, there are 90 serotypes with
different capsular polysaccharides, and seven of
these together cause about 85% of invasive pneu-
mococcal infections in Finnish, Israeli and US
children [25]. Pneumococcal polysaccharide vac-
cines (PPVs) are available which contain the 23
most common pneumococcal serotypes. Children
under 2 years of age respond poorly to all sero-
types, and even respond less well than adults to
some less immunogenic serotypes (6B, 14, 19F,
23F) up to 5–10 years of age [26,27].
Pneumococcal conjugate vaccines require the
individual conjugation of each serotype to a carrier
protein. Most pneumococcal conjugate vaccines
have involved the same carrier proteins as used
for Hib, although novel carriers are under inves-
tigation.
A heptavalent pneumococcal conjugate vaccine,
using CRM197 as carrier, has been used in two
double-blind control trials. In the first study [28],
comprising 37 868 infants immunized at 2, 4, 6 and
12 months, the vaccine was 97.4% protective
against invasive disease caused by vaccine sero-
types (93.9% on an intention-to-treat analysis). In
the second study, which looked at acute otitis
media [29], the same vaccine reduced the number
of culture-confirmed pneumococcal cases of otitis
media by 34% and episodes due to vaccine ser-
otypes by 57%. The overall number of episodes of
acute otitis media, however, was only reduced by
6% (95% CI 4–16%), due to serotype replacement.
Neisseria meningiditis
The serogroup B meningococcal polysaccharide, a
homopolymer of sialic acid residues, is poorly
immunogenic at any age. This may be because
of structural similarities to brain glycoproteins.
Purified capsular polysaccharides from ser-
ogroups A, C, W135 and Y have been used in
vaccines. Serogroup C polysaccharide is not
immunogenic in children under 2 years of age,
although serogroup A polysaccharide is unusual
in eliciting an antibody response and priming in
infants as young as 3 months of age [30].
Conjugate vaccines using A and/or C polysac-
charides are safe and immunogenic [31,32]. In the
Gambia, however, while the C conjugate vaccine
induced memory, the A conjugate did not [31]. The
reasons for the different behaviors of A and C
polysaccharides and conjugates are still being elu-
cidated.
A meningococcal serogroup C conjugate vac-
cine, with CRM197 as the carrier, was introduced
in the UK for infants, toddlers and teenagers [33].
The estimated short-term efficacy of the vaccine,
based on surveillance data, was 97% for teenagers
and 92% for toddlers (aged 1–2 years); the data for
protection are not yet available.
Salmonella typhi
The capsular polysaccharide of Salmonella typhi,
Vi, is an essential virulence factor, and is protec-
tive in children over 5 years of age. There is also a
live attenuated vaccine available but it also is not
very effective in young children. Conjugates have
been developed using a Pseudomonas aeruginosa
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recombinant exoprotein A (rEPA) as a carrier. This
vaccine is safe and immunogenic in children as
young as 2 years of age [34], and proved to be
91.5% protective against infection in 2–5-year-old
Vietnamese children [35].
Group B streptococcus
Group B streptococci (GBS) represent the leading
cause of neonatal septicemia and meningitis in
industrial countries. The response of normal
adults to GBS polysaccharide vaccines is subopti-
mal [36]. Conjugate vaccines are immunogenic in
laboratory animals [37–39], and a tetanus toxoid-
based conjugate of type II was immunogenic in
healthy women [40].
Others
A conjugate vaccine which is immunogenic in
animals has been developed against Staphylococcus
aureus [41,42] and is undergoing clinical trials.
The safety, immunogenicity and efficacy of the
vaccine with S. aureus types 5 and 8 capsular
polysaccharides conjugated to rEPA from P. aeru-
ginosa was assessed in patients with end-stage
renal disease, who frequently have staphylococcal
infections [43]. A single dose conferred partial
immunity (57% efficacy) for approximately
40 weeks.
Escherichia coli polysaccharide conjugated to
rEPA from P. aeruginosa [44] and a conjugate pre-
paration from Shigella spp. [3] are also being devel-
oped.
Safety
Polysaccharide vaccines have been in use for sev-
eral decades and have proved to be very safe.
There has been less experience with conjugate
vaccines but, to date, the safety record is also very
good.
Suppressive effects—administration with
other vaccines
There are now numerous reports (reviewed in
[45]) that the vaccine diphtheria tetanus acellular
pertussis (DTaP) administered in the same syringe
with PRP–T induces significant suppression of the
PRP and tetanus antibody responses, an effect
considered to be due to antigenic (T) competition.
This effect was not significant if the preparations
were administered separately.
Comparison of the pneumococcal
polysaccharide and conjugate vaccines
It is expensive to make one vaccine containing
many conjugate preparations, each with a different
polysaccharide specificity, to control a single dis-
ease caused by one agent, e.g. the 23 different
specificities in the pneumococcal polysaccharide
vaccine. Because of this, there is still some interest
in looking for a way of making a polysaccharide
vaccine more protective for the young, such as
increasing the extent of interaction between the
polysaccharide-binding B-cell and activated, non-
antigen-specific T-cells.
Because of the complex immunization schedule,
it would be advantageous to combine the conju-
gate vaccines with other vaccines. Suggested com-
binations include Hib/DTP(DTaP) and Hib/DTP/
HepB.
The major advantage of conjugate vaccines is
their ability to induce protective levels of immu-
nity in very young children, thus meeting a major
need. The Hib conjugate in particular has achieved
this goal so effectively that there is now great
interest in including this vaccine in global vaccina-
tion programs.
Will the advent of conjugate vaccines result in
the phasing out of polysaccharide vaccines?
Immunologically, there is reason to believe that
the conjugate vaccines will be equally and very
likely more effective than the corresponding poly-
saccharide vaccines in all age groups. This will
happen over time, one exception being the 23-
valent pneumococcal vaccine given, in particular,
to the elderly. However, as administration of poly-
saccharide vaccines can boost the earlier response
to the conjugate vaccine, boosting an earlier
response to the heptavalent conjugate pneumococ-
cal vaccine with the 23-valent polysaccharide vac-
cine would be rational. It could be adopted as a
more effective way to protect the elderly against a
wide range of pneumococcal strains.
C O N C L U S I O N
There is no other example where the introduction
of a new approach to vaccine development has had
such a rapid and positive effect in preventing
infections by a series of human pathogens. Live,
attenuated viral vaccines have been highly suc-
cessful in most cases, but their development has
occurred over a prolonged period. The current
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progress with conjugate vaccines has occurred
over two decades, and for a group of bacterial
pathogens for which it had previously proved
difficult to develop highly effective vaccines, espe-
cially for young children.
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